|
||||||||||||||||
|
||||||||||||||||
The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. new drug development, 41 recommendations for research, 5, 87 relapse behavior, 69 Antiaddiction medications, 27, 29. See also Pharmacotherapy Antisocial personality, 123, 181 Anxiety disorders, 211 Arachidonic acid, 59 Assessment instruments, 201-202, 239 B Barbiturates, 66 Behavioral research in abuse liability research, 38-39 on aggression and violence, 47-48 behavioral models, 36-37 craving response, 46-47 economic modeling, 49-50 future prospects, 50-51 learning and conditioning in treatment models, 41-42 on motivation for drug use, 43-45 neuroscience research and, 37-38 for pharmacotherapies, 39-41, 203 risk factors for drug use, 48-49 on withdrawal, 42 Benzodiazepines, 211 antagonists, 70 Bromocriptine, 71 Buprenorphine, 195-196 C Ca2+ neurotransmitter pathway, 59, 60 Cannabis. See Marijuana Cerebral blood flow measurement, 73 Children/adolescents antismoking campaigns, 145-146 community-based preventive interventions, 146 confidentiality issues in treatment, 270 consequences of prenatal drug exposure, 170-171, 174-175 developmental risks in drug use, 8, 166-167 epidemiological surveys, 99-101, 106 parental drug abuse, 175 peer risk factors, 125-126 predictors of adult substance abuse, 122-123 preventive intervention design, 140 racial differences in drug use, 128 risk factors, 128-129 school-based prevention programs, 141-143, 147-149, 152 treatment considerations, 214-215 Clorazepate, 211 Cocaine aggressive behavior and, 47 antiaddiction medications, 203 brain glucose metabolism in use of, 73 craving response in users, 46-47 day hospital vs. inpatient treatment, 240-241 dopaminergic effects, 37, 64, 73, 82 drug interactions, 173 effects on male reproduction, 174 extent of dependence, 102 market characteristics, 260 maternal use during pregnancy, 166, 167 neurochemical response, 61, 64, 68 pharmacological antagonists, 70 prenatal exposure, 171-172 treatment vs. drug control/interdiction, 199-200 violence linkage, 178-179 See also Crack cocaine Cognitive-behavioral psychology, 42, 196 Community Epidemiology Work Group, 105
|
|
|||||||||||||||
